SOPHiA GENETICS Expands Collaboration with AstraZeneca to Advance Breast and Prostate Cancer Detection
Tuesday, September 23, 2025
SOPHiA GENETICS has announced an expanded partnership with AstraZeneca to improve the detection and treatment of breast and prostate cancer.
The announcement was made at the World CB & CDx Summit in Boston.
The collaboration is centred on developing an optimised next-generation sequencing (NGS) solution to analyse genetic mutations in the PIK3CA/AKT1/PTEN pathway. This pathway plays a key role in controlling cell growth and survival, and its disruption is linked to cancer development. Mutations in the PTEN gene, in particular, are known to drive tumour growth and resistance to therapies.
Together, the companies have created an enhanced NGS tool that uses AI to detect genomic alterations across the full PTEN gene. Early prototypes have shown improved sensitivity in identifying complex mutations.
It will introduce a Privileged Access Programme for selected laboratories specialising in breast and prostate cancer research. This programme will allow validation of the tool’s sensitivity in clinical settings, with broader commercial availability planned for 2026. A multi-centre real-world study will also be conducted to assess its effectiveness further.
The partnership will make use of SOPHiA GENETICS’s global network to support wider adoption of PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy.
The aim is to expand access to precision therapies and strengthen innovation in precision oncology worldwide.
Source: sophiagenetics.com
